Humanin vs FOXO4-DRI
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: HN, HNG (S14G-humanin)
Humanin is a 24-amino-acid peptide encoded inside mitochondrial DNA (in the 16S rRNA gene), discovered in 2001 and named for its ability to protect human neurons from Alzheimer-related cell death. It was the first member of the mitochondrial-derived peptide family and is studied mainly for neuroprotection, cell survival, and metabolic and age-related disease. The honest status: it has the deepest preclinical evidence base of any mitochondrial peptide, but human therapeutic trials are essentially absent.
Also: FOX04-DRI, FOXO4 D-Retro-Inverso
FOXO4-DRI is an experimental senolytic peptide, meaning it is designed to kill off worn-out 'zombie' cells (senescent cells) while leaving healthy ones alone. It comes from a single influential 2017 mouse study and is engineered with a clever stability trick. It has never been tested in a human clinical trial, so anything beyond 'promising in mice' is speculation.
Key Comparison Insights
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Humanin | FOXO4-DRI |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Humanin is fundamentally a cell-survival signal that blocks apoptosis, the programmed self-destruct cells run when stressed. It binds a trimeric receptor complex made of CNTFR, WSX-1, and gp130 on the cell surface, switching on JAK2/STAT3 survival signaling. Inside the cell it directly grabs the pro-apoptotic protein BAX and stops it from moving to the mitochondria and punching holes in the membrane, which is the step that would otherwise commit the cell to death. It also binds IGFBP-3, modulating IGF-1 signaling and further dialing down apoptosis, and it interacts with formyl peptide receptors. The throughline across all of these is the same: keep stressed cells alive and protect mitochondria. | Senescent cells should die but don't, partly because the protein FOXO4 holds p53 hostage in the nucleus, keeping the cell's self-destruct program switched off. FOXO4-DRI is a peptide based on a FOXO4 sequence that competes for that interaction, freeing p53 and pushing it out of the nucleus, which triggers p53/p21-dependent apoptosis selectively in senescent cells. The 'DRI' stands for D-retro-inverso: the peptide is built from D-amino acids in reversed order, a design that resists enzyme breakdown and improves stability while preserving the binding shape. The selectivity is the appeal, since healthy proliferating cells are largely spared in the preclinical work. |
| Common Dosing | 5-10 mg weekly divided into 2-3 injections 2-3x weekly (e.g., Monday, Wednesday, Friday) | 2-10 mg every other day for 3 doses (one cycle) 3 doses every other day, 1-3 cycles per year |
| Administration | Injection (route varies) | Subcutaneous injection (community), IV/IP in animal studies |
| Typical Duration | Variable | 1 cycle = 3 doses over 5-6 days, repeat 1-3x yearly |
| Best Time to Take | Morning | Per research protocol |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Humanin is one of the best-characterized mitochondrial peptides in the lab, with a large body of in vitro and animal work. It protects neurons against amyloid-beta toxicity, shields retinal pigment epithelium cells from oxidative stress and senescence, and shows protective effects in models of cardiovascular disease and diabetes. Circulating humanin declines with age in humans, and some studies link higher endogenous levels to better metabolic and longevity markers, which fuels the longevity interest. But that is association and animal data, not proof that taking humanin treats any disease. There are no large completed randomized human trials demonstrating clinical benefit, and most of what is sold to consumers is synthetic humanin or analogues like HNG, used far ahead of the evidence. It is a compelling research molecule, not a validated drug. | The foundational study (Baar et al., Cell, 2017) reported that FOXO4-DRI selectively pushed senescent cells into apoptosis and, in mice, restored fur density, kidney function, and physical fitness, and helped counteract the toxicity of the chemotherapy drug doxorubicin. That is a striking result and it kicked off real interest in senolytic peptides. A few honest caveats. Some vendor and blog claims, like a specific percent lifespan extension, are not supported by the original paper and appear fabricated. Independent groups have since shown FOXO4-DRI can clear senescent human cells in culture (for example, expanded chondrocytes), and newer peptides report being several-fold more potent. Bottom line: the mouse and in vitro data are interesting, but there are no published human clinical trials, no established safe human dose, and long-term safety is unknown. |
Frequently Asked Questions: Humanin vs FOXO4-DRI
What is the difference between Humanin and FOXO4-DRI?
Humanin is a anti-aging peptide that humanin is a 24-amino-acid peptide encoded inside mitochondrial dna (in the 16s rrna gene), discovered in 2001 and named for its ability to protect human neurons from alzheimer-related cell death. it was the first member of the mitochondrial-derived peptide family and is studied mainly for neuroprotection, cell survival, and metabolic and age-related disease. the honest status: it has the deepest preclinical evidence base of any mitochondrial peptide, but human therapeutic trials are essentially absent. FOXO4-DRI is a anti-aging peptide that foxo4-dri is an experimental senolytic peptide, meaning it is designed to kill off worn-out 'zombie' cells (senescent cells) while leaving healthy ones alone. it comes from a single influential 2017 mouse study and is engineered with a clever stability trick. it has never been tested in a human clinical trial, so anything beyond 'promising in mice' is speculation. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Humanin or FOXO4-DRI?
Neither is universally "better" - the choice depends on your specific goals. Humanin is typically used for anti-aging purposes, while FOXO4-DRI is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Humanin and FOXO4-DRI be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Humanin and FOXO4-DRI together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.